Use of leukemia-derived cells in ovarian cancer vaccines
AssigneeDcprime B.V.
InventorsErik Hans Manting, Satwinder Kaur Singh, Jeroen Rovers
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods for treating a progressive ovarian cancer using an allogeneic leukemia-derived cell. Also provided are immunogenic compositions comprising an allogeneic leukemia-derived cell, and pharmaceutical compositions and formulations thereof.
Claims31
A method of treating a progressive ovarian cancer in a subject in need thereof, comprising:
- selecting a subject having had an initial treatment for the ovarian cancer;
- and
- administering to the subject an effective amount of an immunogenic composition comprising an allogeneic leukemia-derived cell.
3-9. (canceled)
11-20. (canceled)
22-31. (canceled)
33-38. (canceled)
A method of treating a progressive ovarian cancer in a subject in need thereof, comprising:
- administering to the subject an effective amount of an immunogenic composition comprising an allogeneic leukemia-derived cell.
41-48. (canceled)
50-59. (canceled)
61-63. (canceled)
65-71. (canceled)
73-80. (canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.